Moxa-s New Dual-RF Wireless Technology Enables Reliable Train-to-Ground Communications for Brazilian Railway

Moxa-s New Dual-RF Wireless Technology Enables Reliable Train-to-Ground Communications for Brazilian Railway

Munich, November 8th, 2010

Moxa-s next generation AWK-6222 and AWK-5222 dual-RF wireless AP/Bridge/Clients were chosen to create train-to-ground communication networks in Sao Paulo, Brazil"s largest city.

In this project, industrial-grade WLANs are responsible for on-board video surveillance, passenger information systems, and train control, which are important components in ATO (Automatic Train Operations) and ATC (Automatic Train Control). Moxa"s wireless networks allow rail opera

KP2 GmbH signs further cooperation contracts offering efficient sales consultancy and the field-tested Miller Heiman Sales System on a European base

KP2 GmbH signs further cooperation contracts offering efficient sales consultancy and the field-tested Miller Heiman Sales System on a European base

Amberg / Germany, November 2010.
KP2 GmbH, a German based consulting firm focusing on sales performance and sales excellence, is expanding its partner network to the European market. With new cooperation partners in Spain, Italy, France, the Netherlands, Scandinavia, Turkey and Czech Republic, KP2 grows as a Pan-European sales consulting organisation.

KP2 GmbH and its partner organisations will jointly offer the full services and tools of KP2 and Miller Heiman, the world leading company in Sal

AiCuris Presents Preclinical and Phase 1 Data of its anti-HSV drug AIC316

AiCuris announced today the presentation of preclinical and Phase 1 data on AIC316 at the Antivirals Congress in Amsterdam, Netherlands, from 7th – 9th of November 2010. AIC316 is a novel anti-HSV drug currently in clinical phase 2 testing.
AiCuris scientist and project leader Dr. Alexander Birkmann will give an overview on the pharmacokinetic-pharmacodynamic relationship of AIC316 by presenting efficacy data from experiments performed in a murine infection model and Phase 1 pharmacokin